Exploring Epigenetic Editing Approaches to Target Fibrotic Drivers, Enable Precision Modulation & Expand Next-Generation MASH Therapeutic Strategies

•  Inhibiting the pleiotropic fibrotic processes driving MASH via nonpermanent epigenetic editing (‘epi-editing’); enabling precision therapeutic intervention and expanding next-generation MASH development strategies
• Leveraging epi-editing to develop innovative and differentiated next-generation therapeutic strategies to treat steatosis and fibrosis in MASH
• Expanding pipeline opportunities by tackling undruggable targets through epi-editing gene activation or repression

Speakers:

Amy Curley

Vice President, Discovery Biology

Sepia Therapeutics